Alzheimer’s Dementia Vaccine To Be Tested In Humans

According to the international media, we are ready to take advantage of yet another advent of science: the dreamed-of vaccine against dementia caused by Alzheimer’s, which, as it is in the final stages of testing, should soon be tested in humans.

The immunizing agent, according to the portal Reasons to Believe, was developed in partnership by researchers from the University of California, in the United States, the University of Flinders, in Australia, and the Institute of Molecular Medicine, also in the United States.

So far, the vaccine has shown promising results in tests that have been carried out with mice. Because of the latest analysis , researchers believe the product can be used in tests with human patients.


As experts explain, both dementia and Alzheimer’s are diseases that cause cognitive clinicians. In short, these declines arise due to the accumulation of certain proteins in the brain, which, at a certain point, start to cause some neurological damage.

The good news is that the vaccine promises to stop the accumulation of these proteins. With this, the immunizing agent ends up also helping to stop the drastic neurodegeneration that occurs in the area. The latest analysis by researchers involved in the production of the vaccine showed that brain problems with the same characteristics were eliminated in mice and the deficiency, at a certain point, regenerated itself.

In an interview with the BBC, Nikolai Petrovsky, an endocrinologist and one of those responsible for the production of the immunizing agent, validated the fact that “the tests yielded excellent and encouraging results”. Also according to the professional, the research team should, in the coming months, provide the necessary demand to start the tests on humans.

According to the portal Reasons to believe, the study period in humans will be carried out for a period of up to 2 years, at which time, probably, science will no longer be so focused on the new coronavirus.

For Nikolai, “this was a great achievement for the beginning of this decade”. The professional believes that the arrival of the vaccine will systematically influence the fight against Alzheimer’s, whose current treatments are based on drugs that only help to delay the disease – and still without guarantee.


The definition of Alzheimer’s provided by the MSD Manual portal – first published in 1899 as a small reference book for doctors and pharmacists – classifies the disease as a type of “dementia that, in addition to causing a slow and progressive decrease in mental function , it also directly affects memory, thinking, judgment and the ability to learn”.

Also according to the manual, Alzheimer’s dementia affects 60 to 80% of the elderly. The document also points out that the existence of the disease in people under 65 years of age is extremely rare.

Currently, in the United States, the disease is found in 10% of people aged 65 and over – and, in addition, it affects women more than men, in part because women live longer. The percentage, meanwhile, increases with age: from 65 to 74 years, 3%; from 75 to 84 years old, 17% and from 85 years old or more, 32%.

The cause of the disease remains unknown,  but it is believed that, as the manual points out, it comes from genetic factors.